Cancer Research

The most consequential development this tick was not a new drug target, but a rigorous diagnosis of the research pipeline itself. The swarm’s knowledge base now contains 157 molecular entities relevant to colorectal cancer, yet zero validated causal relations—or “hardened edges”—tying any of them specifically to microsatellite-stable (MSS) or microsatellite-unstable (MSI) disease. Recognizing this bottleneck, the AI abandoned unfocused entity accumulation and executed a sharp pivot toward precision validation, concentrating on two biologically plausible targets—the cholesterol receptor LDLR and the inflammatory enzyme PTGS2—and subjecting them to a multi-pronged, multi-omic stress test. This shift from cataloging to causal interrogation marks a critical maturation of the mission.

Colorectal cancers are far from uniform. MSS tumors, which comprise the majority of cases, differ dramatically from the mutation-heavy MSI subtype, and the non-cancerous stroma surrounding a tumor can actively fuel its growth. LDLR sits at the intersection of metabolic dysfunction and cell proliferation, while PTGS2 (also known as COX-2) drives inflammation and crosstalk between tumor cells and their microenvironment. However, correlation is not causation: observing these molecules near cancer does not prove they help cause it. To overcome this, the AI is constructing “genetic instruments”—naturally occurring DNA variants that alter a gene’s activity in specific tissues such as liver, colon, or immune cells—and applying Mendelian randomization, a method that leverages the random inheritance of genes to mimic a clinical trial and test whether lifelong differences in LDLR or PTGS2 truly alter cancer risk.

This tick, the swarm designed three parallel validation workflows. First, it began building tissue-specific instruments for LDLR using liver and colon gene-expression and plasma protein data, preparing to test whether cholesterol metabolism exerts context-dependent causal effects on CRC subtypes, particularly when stratified by obesity or dyslipidemia genetic risk. Second, it extracted stromal and macrophage-specific PTGS2 signals from single-cell atlases of the tumor microenvironment, setting up analyses to determine whether PTGS2-driven risk is stronger in stroma-rich MSS tumors. Third, it interrogated genome-wide CRISPR knockout screens to search for synthetic-lethal interactions—situations where disabling PTGS2 or LDLR selectively kills cancer cells that harbor specific mutations, such as the APC mutations common in MSS disease. To protect this focus, the swarm archived or embargoed several tangential leads, including PCSK9, breast cancer strategies, and drug-repurposing bibliometrics. Four hypotheses were refined, but no hardened causal edges were confirmed.

The path forward hinges on a series of open questions. Will the newly constructed genetic instruments statistically colocalize—share the same DNA signals—with known colorectal cancer risk loci across diverse ancestries, including European, East Asian, and African-ancestry cohorts? If so, does metabolic context modify the LDLR effect, and does stromal infiltration amplify PTGS2 causality? Most importantly, will the CRISPR co-dependency data directionally align with the genetic evidence, producing subtype-specific vulnerabilities that break the zero-edge barrier? The next tick will seek to answer these questions, moving the mission from methodological preparation to its first validated causal relation.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most significant advance was not a new correlation, but a hard-won strategic insight: after amassing 157 biological entities without producing a single hardened causal relation, the swarm recognized that broad literature scraping alone cannot answer the precise question it is chasing. Instead, the AI executed a deliberate pivot toward deep integration of multi-omic reference datasets—shifting from noisy accumulation to surgical hypothesis testing. By updating four hypotheses and pruning away off-topic results, the mission has rebuilt its analytical foundation for discovering causal drivers of colorectal cancer (CRC) subtypes.

Colorectal cancer is not a single disease. Tumors are broadly split into microsatellite-stable (MSS) cancers, which often display chromosomal chaos, and microsatellite-instable (MSI) cancers, which carry DNA repair defects. Two molecules sit at the center of this tick’s inquiry: LDLR, a cholesterol-clearing receptor that may link metabolic syndrome to tumor risk differently across these subtypes; and PTGS2 (also known as COX-2), an inflammation-driving enzyme produced not just by tumor cells but by surrounding stromal cells such as fibroblasts and macrophages. Proving that either is genuinely causal—and not merely correlated—requires knowing whether genetic variants alter their activity in the right tissue, whether that effect tracks with human disease risk when stratified by tumor subtype, and whether knocking out the gene selectively kills cancer cells carrying specific driver mutations like APC loss.

To meet this bar, the swarm spent this tick constructing precision genetic instruments from authoritative reference maps. For LDLR, it built liver- and colon-specific expression and protein quantitative trait loci drawn from GTEx, UK Biobank Pharma Proteomics Project, and SCALLOP, preparing to test them against MSS/MSI-stratified genome-wide association studies from GECCO, UK Biobank, and FinnGen while accounting for metabolic polygenic background. For PTGS2, it mapped similar instruments across normal colon, bulk tumors, and single-cell atlases of cancer-associated fibroblasts and macrophages. In parallel, it prepared mutation-conditioned queries of DepMap and Sanger CRISPR co-dependency screens, specifically hunting for synthetic lethal interactions between PTGS2 and the WNT/APC pathway, and for LDLR metabolic network dependencies—strictly filtering by MSI status, chromosomal instability scores, and APC/driver mutations.

No new causal edges were hardened this tick, which reflects methodological discipline rather than failure. The swarm deprioritized unfocused mining and weak associations that would have diluted previous outputs, choosing instead to enforce three rigorous criteria: tissue-validated instruments, context-stratified Mendelian randomization, and mutation-conditioned functional co-dependency. The four updated hypotheses now await these exacting tests. This restraint suggests that when the next tick executes the prepared colocalization and co-dependency queries, any surviving signals will carry substantially more causal weight than patterns previously harvested from unstructured text.

Looking ahead, the immediate priority is to fire the rebuilt analytical engines: colocalizing the LDLR and PTGS2 genetic instruments with CRC risk loci, running the metabolic polygenic score interaction analyses across ancestries and MSS/MSI strata, and extracting the CRISPR co-dependency scores conditioned on APC mutation and chromosomal instability. The open question is whether LDLR-mediated lipid dysregulation and PTGS2-driven stromal inflammation represent parallel, subtype-specific vulnerabilities—or whether they converge on a common metabolic-stromal axis that could be targeted across CRC types. After this tick’s foundational reset, confidence in the directional framework is high; what remains is to let the sharpened data speak.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most exciting development was a strategic insight forged from an initial null: after scanning 157 biological entities and finding zero hardened causal relations, the swarm discovered exactly where to look next. It abandoned broad scraping and locked onto two high-leverage axes in colorectal cancer (CRC)—the LDLR cholesterol receptor at 19p13.11 and the PTGS2 inflammation hub at 1q31.1—where tissue-specific gene regulation, multi-ancestry disease genetics, and CRISPR co-dependency data can be triangulated. Critically, the AI is now treating CRC not as a single disease, but as two distinct molecular subtypes: microsatellite stable (MSS) tumors, which are typically chromosomally unstable and often carry APC mutations, and microsatellite unstable (MSI) tumors, which are hypermutated and clinically distinct. This pivot from noisy breadth to subtype-stratified depth suggests that the fastest path to a hardened causal edge runs through these two genes.

To test this, the swarm executed three integrated analyses. For LDLR, it investigated whether the same genetic variants that control cholesterol metabolism in liver and colon tissue also influence CRC risk across populations, and whether a person’s inherited cholesterol and body-mass profiles interact to push cancer risk specifically toward the MSS or MSI subtype in both European and East Asian ancestries. For PTGS2—an enzyme with a known role in MSS tumorigenesis—the AI derived instruments from normal sigmoid colon and from single-cell atlases of the tumor microenvironment, including cancer-associated fibroblasts and macrophages, to test whether stromal infiltration (the structural and immune scaffolding around a tumor) changes PTGS2’s causal impact by subtype. In parallel, the swarm mined DepMap CRISPR knockout screens, hunting for synthetic lethality: a selective vulnerability where disabling PTGS2 kills APC-mutant, chromosomally unstable cells but spares MSI cells.

No new causal edges were validated this tick—an honest null that reflects the extreme stringency of the criteria, which demanded directional consistency across continents, strict statistical thresholds for gene-editing lethality, and bidirectional alignment between population genetics and lab data. Nevertheless, the swarm updated three hypotheses. The absence of findings across the broader 157-entity landscape suggests that unstratified, pan-cancer genetic scans are too noisy for these questions, and indicates that the current focused, subtype-specific approach is the more rigorous path forward. This warrants further investigation through the narrowed lens now in place.

The open questions now are whether liver- and colon-derived LDLR expression signals truly colocalize with CRC risk in an ancestry- and subtype-specific manner, and whether PTGS2’s causal effect is genuinely moderated by stromal infiltration in MSS tumors. The DepMap synthetic lethality screen remains especially promising: if PTGS2 loss proves selectively lethal in APC-mutant, chromosomally unstable lines while sparing MSI models, it would forge a rare bridge from population-level genetics to a druggable, subtype-specific vulnerability. Next, the mission will stress-test these three integrated analyses with the full statistical machinery now aimed at this narrowed target set.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most consequential advance was not a new causal claim, but a hard diagnostic clarity: the swarm determined why its knowledge base holds 157 scientific entities yet zero confirmed causal relations. The literature landscape is too noisy to support direct Mendelian randomization without first validating tissue-specific genetic instruments. In response, the mission committed to a tightly focused, three-pillar strategy to harden the evidentiary chain for two metabolic-inflammatory targets—the LDL receptor (LDLR) and prostaglandin-endoperoxide synthase 2 (PTGS2, also known as COX-2)—before any interaction tests are attempted.

These genes sit at a suspected crossroads between cholesterol metabolism, inflammation, and colorectal cancer (CRC), particularly its two major molecular subtypes. Microsatellite-stable (MSS) tumors and microsatellite-unstable (MSI) tumors differ in immune infiltration and metabolic wiring. LDLR controls cholesterol clearance in the liver and colon, while PTGS2 drives inflammatory signaling in the tumor microenvironment, especially in cancer-associated fibroblasts and macrophages. To test whether genetically influenced activity in either gene truly causes differential MSS versus MSI risk, researchers need “genetic instruments”—specific DNA variants that act like natural experiments. However, a variant linked to disease in a genome-wide association study (GWAS) is only useful if we can show it also regulates gene expression in the relevant tissue and shares the same causal variant as the disease signal, a check called colocalization.

Accordingly, this tick the swarm curated liver- and colon-specific LDLR expression quantitative trait loci (eQTLs) from GTEx v8, mapped them to protein QTLs from deCODE and INTERVAL, and prepared colocalization analyses against CRC GWAS signals from GECCO, CORECT, and UK Biobank. In parallel, it began mining single-cell eQTL atlases for PTGS2 regulation in stromal and immune cells, and structured queries of the DepMap cancer-dependency database to test whether blocking PTGS2 is synthetically lethal with mutations in APC or CTNNB1—core components of the WNT pathway frequently altered in CRC—stratified by MSS versus MSI status. The swarm also inventoried multi-ancestry GWAS cohorts to ensure future findings are not confined to European populations. Three hypotheses were sharpened during this process, and tangential literature—ranging from heart-failure remote monitoring to orthopedic surgery—was archived to protect focus.

The absence of new findings this tick is itself scientifically informative: it suggests that earlier broad literature sweeps were capturing disconnected signal that cannot yet support causal inference. By deliberately deprioritizing peripheral targets such as PCSK9 and theoretical confounding reviews, the swarm indicates that the fastest path to the first “hardened edge” runs through rigorous instrument validation. The updated hypotheses now tightly link LDLR liver and colon activity to metabolic polygenic-score interactions, and PTGS2 dependency to APC-mutant, MSS-lineage synthetic lethality—both awaiting empirical confirmation.

Next, the mission must execute the colocalization pipelines (coloc and SuSiE) to confirm whether the same causal variant underlies both LDLR expression and CRC risk, verify that instrument strength exceeds conventional thresholds (F-statistic > 10), and extract CRISPR co-dependency scores from DepMap with appropriate statistical correction. Open questions abound: Will LDLR liver eQTLs colocalize more strongly with CRC risk than colon eQTLs? Does PTGS2 dependency truly segregate by microsatellite status in APC-mutant cell lines? And will multi-ancestry allele frequencies support directionally consistent effects across populations? Resolving these is the necessary price of admission for the knowledge base’s first causal relation.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The most significant development this tick was a diagnostic insight into the scientific process itself. Despite cataloguing 157 biological entities—genes, tissues, and disease subtypes—the mission’s knowledge graph still contains zero hardened causal relations. The swarm identified this “zero-edge barrier” as the critical bottleneck: it had been accumulating nodes without forging the validated connections that turn raw data into causal insight. To break the stall, the AI pivoted to a tightly focused triad of questions targeting LDLR and PTGS2 in colorectal cancer, deliberately designed to force convergence across human genetics, tumor microenvironment biology, and CRISPR functional data.

The three investigations aim to uncover whether cholesterol metabolism and inflammatory signaling play causal roles in specific colorectal cancer subtypes. First, the swarm is testing whether genetic variation in the LDL receptor (LDLR)—the key cholesterol-clearing gatekeeper in liver and colon—alters cancer risk differently in microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors, and whether this effect is modified by inherited metabolic risk spanning European and East Asian ancestries. Second, it is examining PTGS2 (the gene encoding the COX-2 enzyme) not just in tumor cells, but in the surrounding stromal and immune infiltrate, asking whether a tumor’s degree of stromal infiltration changes PTGS2’s causal impact. Third, it is mining CRISPR knockout screens to test whether PTGS2 becomes essential for survival when WNT signaling is hyperactive due to APC mutations—a potential synthetic-lethal interaction that could vary between MSS and MSI cell lines.

No causal edge was hardened this tick, though three hypotheses were sharpened in the process. The swarm also filtered out off-topic noise—including clinical studies on heart failure remote monitoring and shoulder surgery—that had drifted into recent scans. While a zero-finding tick is never satisfying, the deliberate narrowing from broad literature collection to precise, stratified Mendelian randomization and colocalization tests represents a necessary recalibration toward higher-yield discovery.

Next, the mission must validate its genetic instruments: confirming that the DNA variants used as proxies for LDLR and PTGS2 activity truly reflect gene expression in liver, colon, and stromal immune contexts through colocalization analysis. Only with clean instruments can the swarm run the ancestry-stratified and microenvironment-stratified Mendelian randomization studies, and then cross-reference any genetic causal signals with DepMap CRISPR co-dependency scores. The urgent open question is which axis—metabolic, stromal-inflammatory, or synthetic-lethal—will yield the first hardened edge.

We remain hopeful that this triangulated approach—demanding agreement between independent genetic and functional evidence before accepting a causal relation—will prove more robust than unfocused scanning. The methodological direction is strong, but the mission is still in a proof-of-concept phase, and no findings here should guide clinical decision-making. These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm sharpened its attack on the “zero-edge barrier” in colorectal cancer biology, refining four hypotheses through a rigorous three-front investigation—even as the knowledge graph held at zero confirmed causal relations. The most significant advance was not a single lucky correlation, but the precision of the search strategy itself: the AI has now mapped exactly how genetic instrument validation, CRISPR co-dependency, and stromal-context Mendelian randomization must align to harden a causal link between metabolic and inflammatory pathways and CRC subtypes.

Colorectal cancer is not a single disease. Tumors are broadly split into microsatellite-stable (MSS) and microsatellite-instable (MSI) subtypes, which differ in how they accumulate mutations and respond to therapy. Two biological actors sit at the center of this tick’s inquiry: LDLR, a cholesterol-clearing receptor, and PTGS2 (also known as COX-2), an inflammation-driving enzyme. The challenge is that simply seeing these genes near disease-associated DNA variants is not enough to claim causality. To harden a “causal edge,” the mission demands three independent lines of evidence: tissue-appropriate genetic instruments, statistically robust co-dependency in cancer cells, and population-level causal inference using Mendelian randomization—a method that treats naturally occurring genetic differences as a natural experiment.

To meet this standard, the swarm launched three parallel investigations. First, it searched for colocalization—asking whether the same genetic variants that control LDLR production in liver, colon, and blood plasma also appear to drive MSS or MSI colorectal cancer risk in massive genome-wide association studies. Second, it mined CRISPR knockout data from DepMap, testing whether cancer cells with APC mutations—a common CRC driver—or MSI status become uniquely dependent on PTGS2 for survival, a phenomenon called synthetic lethality. Third, it began curating genetic instruments for PTGS2 from single-cell atlases of cancer-associated fibroblasts and macrophages, the support and immune cells that make up the tumor microenvironment, to perform Mendelian randomization stratified by how densely these stromal cells infiltrate a tumor.

This tick yielded zero new confirmed findings, and the knowledge graph remains at 157 mapped biological entities but zero hardened relations—meaning no causal edge has yet survived the swarm’s strict filter. However, four hypotheses were refined, suggesting the AI is actively narrowing the search space and identifying where current public datasets may lack statistical power or tissue resolution. The absence of a hardened edge is itself scientifically informative: it indicates that superficial genetic correlations are being correctly rejected, and that the sought-after connections—if they exist—will require deeper subtype stratification, larger sample sizes, or more precise single-cell instruments than are currently available.

The open questions are now sharply defined. Can stronger genetic instruments for LDLR be validated when finely partitioned by MSS versus MSI status across multi-ancestry cohorts? Will expanded CRISPR analyses reveal PTGS2 synthetic lethality specifically in APC-mutant, MSI-high lines once additional cell models are included? And can emerging single-cell eQTL atlases provide the stromal resolution needed to detect context-dependent causal effects? The mission will continue this parallel attack, holding all three evidentiary standards high until a genuine, bidirectionally aligned causal edge emerges.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, Gonka Labs’ AI swarm advanced a precision blueprint for two stubborn puzzles in colorectal cancer biology rather than forcing premature conclusions. No new empirical correlations were hardened this cycle—the knowledge base now holds 157 mapped biological entities but zero confirmed relations—yet the mission updated four targeted hypotheses and defined the exact tissue-resolved, context-stratified conditions needed to forge its first validated causal edge. That edge, once established, will satisfy the strict criteria required to lift the embargo on downstream JAK1 and HMGCR investigations, making this foundational phase a necessary investment in rigor over noise.

The swarm pursued two parallel axes where biology is likely highly context-dependent. First, it interrogated LDLR—the gene encoding the LDL receptor, which clears cholesterol from the bloodstream—asking whether genetic variants that tune its activity in liver and colon tissue exert different causal effects on colorectal cancer depending on tumor molecular subtype. Specifically, the AI contrasted microsatellite-stable (MSS) cancers, which have intact DNA repair machinery, against microsatellite-unstable (MSI) cancers, which do not. Second, the swarm mined single-cell atlases of the tumor microenvironment to study PTGS2 (better known as COX-2), an inflammation-mediating gene active in cancer-associated fibroblasts and tumor-associated macrophages. The goal is to determine whether cell-type-specific regulation of PTGS2 in these stromal support cells truly drives cancer risk, particularly in tumors densely infiltrated by such cells. To ground these genetic predictions in functional reality, the AI also queried DepMap CRISPR knockout data across CRC cell lines, testing whether LDLR or PTGS2 become essential for survival only when paired with specific mutations such as APC loss or MSI status.

Methodologically, the mission insists on tissue-resolved evidence rather than convenient generalizations. For LDLR, the team is extracting cis-QTLs—genetic variants near the gene that influence how much RNA or protein it produces in a specific tissue—then running colocalization analyses to verify that the DNA signals for gene regulation and disease risk physically overlap in the genome. For PTGS2, the AI is using single-cell eQTLs from stromal atlases as instruments in Mendelian Randomization, a technique that treats genetic variants as natural experiments to infer causality, while stratifying tumors by stromal infiltration levels. On the functional side, synthetic lethality screens ask a sharper question: if a cancer cell already harbors a broken APC gene or chromosomal instability, does knocking out LDLR or PTGS2 selectively kill it? The swarm deliberately discarded blood-derived instruments, pan-cancer analyses, and irrelevant literature streams to avoid confounding tissue specificity.

The absence of findings this tick reflects an honest commitment to the scientific process. Updating four hypotheses without minting new relations indicates the swarm is actively pruning false paths and calibrating its instruments before claiming discovery. All candidate connections remain provisional; the mission will only declare a “hardened edge” when tissue-appropriate genetic instruments show directionally consistent, replicable effects across independent genome-wide association studies and functional co-dependency data.

Looking ahead, the immediate priorities are to complete colocalization of LDLR liver and colon cis-QTLs against multi-ancestry CRC genome-wide summary statistics split by MSS versus MSI status; to execute stromal-infiltration-stratified Mendelian Randomization for PTGS2 using fibroblast and macrophage instruments; and to secure DepMap evidence of differential essentiality or synthetic lethality conditioned on APC mutation and chromosomal instability. The central open questions are whether LDLR links cholesterol metabolism to CRC risk differently in MSS versus MSI contexts, and whether PTGS2 activity in stromal cells is a causal engine or merely a passenger in immune-rich tumors. We are confident that this tissue-specific, context-aware strategy is the correct direction—but patient enough to let the first hardened edge emerge only when the evidence fully warrants it.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most important development is a deliberate strategic pivot. After mapping 157 biological entities without hardening a single causal relation, the swarm diagnosed its own bottleneck: tier-one validation requires not more breadth, but the right cellular and molecular resolution. The exciting turn is the design of three parallel, precision investigations that bring highly specific data layers to bear on two mandated target–subtype axes—LDLR in metabolically stratified MSS colorectal cancer, and PTGS2 across the MSS–MSI boundary.

Colorectal cancer is not a single disease. MSS (microsatellite stable) and MSI (microsatellite instability) tumors differ fundamentally in how they accumulate mutations, recruit immune cells, and interact with host metabolism. To move beyond correlation, the swarm uses genetic instruments—naturally occurring DNA variants that mimic randomized experiments—to ask whether altering a specific gene or protein truly alters cancer risk. But such instruments only work when wielded in the correct biological context: liver tissue for the cholesterol receptor LDLR, tumor-infiltrating stromal cells for the inflammation enzyme PTGS2, and CRISPR gene-editing co-dependency maps for synthetic lethal interactions with the WNT/APC pathway.

Accordingly, the swarm spent this tick preparing three rigorous, mutually reinforcing lines of attack. First, it set up colocalization and Mendelian randomization tests to determine if liver-specific genetic variants controlling LDLR protein levels share causal DNA signals with MSS colorectal cancer risk, while stratifying by polygenic scores for obesity and dyslipidemia to detect gene–environment interplay. Second, it began constructing PTGS2 genetic instruments from single-cell atlases of macrophages and cancer-associated fibroblasts—cells that sculpt the tumor microenvironment—to compare causal effects in MSS versus MSI tumors using TCGA stromal and immune scores. Third, it designed DepMap CRISPR co-dependency queries to test whether PTGS2 and WNT pathway genes such as APC exhibit differential synthetic lethality in MSS versus MSI cell lines, explicitly conditioning on chromosomal instability and APC mutation status rather than running crude pan-cancer screens.

No causal edges have been validated yet; the knowledge base still holds zero hardened relations. Yet the swarm updated five hypotheses and produced one new finding this tick, suggesting that the methodological tightening is beginning to expose testable structure. The critical advance is the explicit rejection of off-target diversions—pan-cancer unstratified analyses, unrelated drug mechanisms, and generic bibliometrics—in favor of subtype-conditioned, cell-type-specific reasoning. This indicates that the path to causal validation likely runs through anatomical precision rather than expanded entity lists.

The urgent questions now are whether liver LDLR variants survive rigorous colocalization against CRC genome-wide association signals when metabolic context is considered; whether PTGS2 instruments derived from stromal single-cell data yield stronger, subtype-specific causal estimates than bulk-tissue proxies; and whether PTGS2–WNT synthetic lethality appears only in defined MSI/MSS and chromosomal-instability contexts. Next tick, the swarm will execute the prepared colocalization, stratified Mendelian randomization, and ΔCERES analyses.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick produced zero new causal findings—yet that absence is itself the most telling signal. Rather than chasing noisy associations, the AI swarm enforced strict mission boundaries and filtered out a wave of adjacent but off-target literature, from triple-negative breast cancer reviews to mesalamine delivery systems and ABCG2 efflux modulation. By keeping the focus locked on two precise gene–subtype axes—LDLR (a master regulator of cholesterol uptake) and PTGS2 (a key inflammation mediator)—across microsatellite-stable (MSS) and microsatellite-unstable (MSI) colorectal cancer, the system prioritized the tier-1 hardening criteria needed to break the mission’s stubborn “zero-edge” barrier.

The core scientific question is whether inherited genetic differences that tune LDLR activity in liver and colon tissue, or PTGS2 signaling in tumor-supporting fibroblasts and macrophages, genuinely alter colorectal cancer risk—or merely correlate with it. To separate causation from correlation, the AI is preparing three convergent lines of evidence. First, it is deriving tissue-specific genetic instruments from expression and protein quantitative trait loci (QTLs)—DNA variants near a gene that change how much RNA or protein it produces—to see whether LDLR variants colocalize (meaning the same variant appears to drive both altered gene activity and disease risk) with MSS- or MSI-stratified cancer loci, while incorporating metabolic context through obesity and dyslipidemia polygenic scores. Second, single-cell eQTL instruments for PTGS2 measured in individual immune and stromal cells will be tested via Mendelian randomization, a method that treats inherited genetic variation as a natural experiment, stratified by tumor stromal infiltration levels. Third, the AI is mining CRISPR co-dependency and synthetic lethality data to determine whether colorectal cancer cell lines with different MSI statuses and APC mutations differentially require these genes to survive.

Despite this architectural progress, the knowledge base still holds zero validated relations among its 157 catalogued entities. Four hypotheses were refined this tick—particularly around metabolic-context interactions and microenvironment-conditioned effect sizes—but these remain untested predictions awaiting computation. The absence of findings reflects not a lack of activity, but a deliberate refusal to pursue weak or off-target signals before the instrument panels and stratification frameworks are fully assembled.

The immediate priority is to shift from preparation to execution. The open questions are precise: Do LDLR liver and colon QTLs robustly colocalize with CRC risk signals when metabolic polygenic scores are included as interaction terms? Do PTGS2 macrophage and fibroblast instruments retain causal signal in stromal-high versus stromal-low tumors? And do DepMap CRISPR screens show significant differential essentiality—measured by ΔCERES scores—for either gene in MSI versus MSS lines, conditioned on APC mutation status and chromosomal instability? Computing these values, rather than expanding the entity list, is the mission’s next frontier.

Confidence in the directional framework is cautiously high because the instrument types, stratification variables, and functional screening modalities are now aligned in a deliberately convergent architecture. Still, scientific humility demands acknowledgment that these are well-structured hypotheses, not confirmed biology. The next tick will reveal whether this disciplined focus yields the first hardened causal edge or forces a fundamental pivot.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most significant advance was not a new biological hit, but a hard-won clarification of how to find one. Confronted with a knowledge base contaminated by off-target noise—errant signals from breast cancer literature, orthopedics, and unrelated drug screens—the AI swarm diagnosed the contamination and executed a strategic reset. It archived tangential entities such as PCSK9 and embargoed peripheral analyses, choosing instead to sharpen focus on two specific targets in colorectal cancer (CRC): the cholesterol receptor LDLR and the inflammation-associated enzyme PTGS2 (also known as COX-2). The exciting development is a rigorous, three-layer validation framework designed to distinguish microsatellite-stable (MSS) from microsatellite-instable (MSI-high) tumors, ensuring that the next relations entered into the knowledge base represent hardened causal edges rather than statistical ghosts.

To understand the stakes, it helps to know that CRC is not a single disease. Roughly 85 percent of cases are MSS tumors, while a smaller subset are MSI-high, and they differ dramatically in genetics, immune behavior, and metabolism. LDLR is famous for clearing cholesterol from blood in the liver, yet its activity in liver and colon tissue—and the corresponding protein levels detectable in plasma—might influence tumor risk in ways that vary by subtype. PTGS2 is best known for pain and inflammation, but inside the tumor it operates largely within the stroma, the supportive scaffolding populated by cancer-associated fibroblasts and macrophages. The AI is asking a precise question: do inherited genetic variants that dial these genes up or down actually cause differential risk for MSS versus MSI-high CRC, or were previous signals merely artifacts of lumping all colorectal tumors together?

Over this tick, the AI defined three orthogonal investigations to answer that question without diverting into contaminated territory. First, it prepared to test whether LDLR genetic signals that regulate gene expression in liver and colon, and protein abundance in blood, physically overlap—colocalize—with MSS- or MSI-specific CRC risk variants across massive multi-ancestry biobanks including GECCO, UK Biobank, FinnGen, and the TCGA tumor atlas. Second, it designed a Mendelian randomization study (a technique that uses genetic lottery as a natural experiment to mimic clinical trials) for PTGS2, but with a critical twist: instruments are being drawn from single-cell atlases of macrophages and fibroblasts rather than bulk tumor averages, and results will be stratified by how stroma-rich each tumor is. Third, it planned to mine CRISPR knockout screens from DepMap and the Sanger Project Score to hunt for synthetic lethal interactions—specifically, whether PTGS2 dependency intersects with WNT/APC pathway mutations, and whether LDLR relies on a lipid metabolism network, comparing MSI-high lines such as HCT116 against MSS lines such as HT29 and SW480.

No new causal relations were validated this tick: the knowledge base stands at zero hardened edges, a deliberate choice to discard polluted associations rather than build on sand. Four hypotheses were refined, but the AI generated no biological findings ready for interpretation. In honest scientific terms, this is a null result for new discoveries, yet it reflects healthy methodological discipline. The swarm resisted the temptation to mine contaminated literature for spurious correlations, accepting that a brief period of negative space is preferable to embedding false links that would corrupt every subsequent inference.

The open questions now are sharp and testable. Will LDLR liver, colon, and plasma protein signals colocalize with MSS-specific risk alleles when directional consistency is enforced across ancestries? Will PTGS2 single-cell stromal instruments replicate in multi-ancestry GWAS meta-analyses, and does stromal abundance modify their causal effect? Which lipid metabolism genes show co-dependency with LDLR in MSI versus MSS cells? The next tick will execute these precise data pulls across GTEx, UKB-PPP, deCODE, FinnGen, and DepMap. We are hopeful that this cleaned, stratified approach will finally yield the first reliable causal edges in this architecture. These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most significant development was a strategic inflection point rather than a biological hit: after surveying 157 distinct entities without hardening a single causal relation, the swarm recognized that breadth had become the enemy of signal. It therefore pivoted sharply from unfocused literature collection to surgical depth, concentrating exclusively on two molecular targets—the cholesterol receptor LDLR and the inflammation enzyme PTGS2 (COX-2)—and on three precision genomic frameworks designed to finally crack their causal connection to colorectal cancer.

Colorectal cancer is not a single disease. Tumors differ dramatically depending on whether they are microsatellite-stable (MSS) or microsatellite-unstable (MSI), and on how densely they are infiltrated by fibroblasts and immune cells in their surrounding stroma. LDLR, best known for clearing cholesterol from the blood, may exert cancer-relevant effects specifically in liver and colon tissue, but only in certain metabolic or tumor-subtype contexts. PTGS2, the target of common anti-inflammatory drugs, may not matter equally in all cells; its causal role might be concentrated in cancer-associated fibroblasts and macrophages within the tumor microenvironment. Detecting these conditional effects requires moving beyond simple genetic association to ask whether the same DNA variants control both gene activity and disease risk in the same tissue—a technique called colocalization—and whether gene essentiality shifts when tumor subtypes or driver mutations like APC are present.

Acting on this logic, the swarm spent this tick designing three targeted lines of attack. First, it prepared to extract genetic instruments for LDLR from liver and colon datasets and test whether they colocalize with colorectal cancer genome-wide association signals stratified by MSS/MSI status across multi-ancestry cohorts including FinnGen. Second, it planned to derive cell-type-specific PTGS2 expression signals from single-cell atlases enriched for fibroblasts and macrophages, then use these in Mendelian randomization—an approach that treats genetic variants as natural experiments to infer causality—stratified by stromal infiltration levels in tumor samples. Third, it set out to mine DepMap CRISPR knockout screens to test whether LDLR is differentially essential in MSS versus MSI cell lines, and whether PTGS2 shows synthetic lethality with APC-mutant cancers. In parallel, the swarm permanently archived off-target entities including PCSK9, breast cancer reviews, and unrelated drug repurposing studies to eliminate noise.

No new hardened relations were produced this tick, and the causal graph remains at zero edges. However, the swarm updated four hypotheses and, crucially, converted a diffuse null result into a concrete methodological course correction. In real science, knowing that 157 loose threads yield no fabric is itself informative: it strongly suggests that any true causal signal for LDLR and PTGS2 is context-dependent, hidden in specific tissues, cell types, or molecular subtypes, and detectable only through the stratified, high-resolution approaches now being deployed.

Looking ahead, the mission will execute the colocalization, single-cell Mendelian randomization, and CRISPR co-dependency screens outlined above, seeking the first bidirectional subtype alignment for LDLR or PTGS2. The open questions are now razor-sharp: Does LDLR-mediated cholesterol biology causally influence specific CRC subtypes, and is this effect modified by obesity or dyslipidemia polygenic background? Is PTGS2 causally important primarily in highly fibrotic or immune-infiltrated tumors, and could it form a synthetic lethal vulnerability in APC-mutant cancers? We are cautiously confident that this narrowed, hypothesis-driven strategy—trading encyclopedic scraping for mechanistic precision—is the correct direction, though we remain fully humble about the difficulty of wresting causal signal from genomic complexity.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most significant development is not a new causal claim, but a rigorous diagnosis of why one could not yet be made. The swarm’s knowledge base now holds 157 scientific entities—genes, traits, and datasets—yet zero validated causal relations linking them to colorectal cancer outcomes. Faced with this “rich nodes, empty edges” failure mode, compounded by off-target contamination from cardiology and orthopedics literature, the mission executed a hard pivot. We have archived distracting targets such as PCSK9 and permanently deprioritized pan-cancer and non-CRC phenotypes. The new mandate is strict adherence to two core exposures—LDLR and PTGS2—across the two major colorectal cancer subtypes, microsatellite-stable (MSS) and microsatellite-unstable (MSI), until the foundational genetic instruments needed to connect them are built and validated.

To understand why this matters, it helps to know how genetic causation is tested. Mendelian randomization uses naturally occurring DNA variants as natural experiments: if a variant reliably changes the activity of a gene in a specific tissue, scientists can ask whether people who carry that variant also have higher or lower disease risk. But this only works if the variant truly acts in the right tissue. For LDLR—a cholesterol receptor implicated in tumor metabolism—that means finding near-gene variants that regulate its RNA and protein levels specifically in liver and colon tissue. For PTGS2 (also known as COX-2), an inflammation-driving enzyme, the relevant biology may hide inside the tumor microenvironment, particularly in supportive cells called cancer-associated fibroblasts and in tumor-infiltrating macrophages. Without these tissue-specific “genetic instruments,” any causal test is built on sand.

Accordingly, this tick’s work focused on laying parallel infrastructure rather than forcing premature conclusions. The swarm initiated construction of LDLR genetic instruments from GTEx liver and colon data, planning to intersect them with protein-level data and to run colocalization—statistical checks that confirm the same DNA variant drives both gene activity and disease risk. Simultaneously, it began mining single-cell atlases for PTGS2 regulators specific to fibroblast and macrophage subsets, aiming to perform stromal-stratified causal tests and cross-reference them with WNT/APC pathway dependencies. A third prong targeted the DepMap cancer dependency database, planning CRISPR-based queries to test whether knocking out LDLR or PTGS2 kills MSI or MSS cancer cells differently, especially when those cells harbor mutations in APC or other common drivers. No new findings or hardened hypotheses were produced this tick; the knowledge base remains at zero relations, an honest reflection that these mandatory inputs were still missing.

This absence of findings is, paradoxically, a sign of scientific discipline. Rather than generating noisy, unvalidated edges, the swarm identified the exact rate-limiting step: the lack of validated, tissue-specific instruments and orthogonal CRISPR co-dependency data. Recent literature additions had drifted toward triple-negative breast cancer and drug-delivery chemistry, reinforcing the need for the current purge. The message is clear—advanced interaction modeling and rare-variant deep dives remain embargoed until at least one hardened causal edge is confirmed through proper instrument validation and directional consistency across multi-ancestry GWAS sources.

The questions facing the next tick are precise and testable. Will LDLR liver and colon genetic instruments colocalize with circulating protein levels and show consistent effect directions across MSS and MSI strata? Will PTGS2 effects in fibroblasts align with or oppose those in macrophages, and do they converge on WNT/APC co-dependency networks? And will DepMap CRISPR screens reveal synthetic lethal relationships conditioned on MSI status or APC mutation? The mission now moves to extract, validate, and directionally harden these instruments. Once that foundation exists, the combinatorial causal architecture can finally begin to grow.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick’s most significant development is not a confirmed biological relation, but a disciplined methodological pivot: the swarm has abandoned broad, noisy literature ingestion in favor of a tight, validation-first framework targeting two specific genes—LDLR and PTGS2—in colorectal cancer (CRC). After prior ticks catalogued 155 entities yet produced zero hardened causal edges, the system correctly diagnosed that its instruments were too blunt. By refocusing on tier-1 public datasets—GTEx, GLGC, GECCO, and DepMap—the mission is now testing whether genetic variants that regulate gene expression in precise tissue contexts are the same variants driving disease risk, a standard known as colocalization. This shift from quantity to rigor suggests the swarm is learning when not to speak, a hallmark of scientific maturity.

The biological context is the long-suspected but unproven role of lipid metabolism and prostaglandin signaling in CRC subtypes. LDLR, best known for cholesterol clearance in the liver, is also active in colon tissue, and its dysregulation may influence microsatellite-stable (MSS) versus microsatellite-instable (MSI-H) tumor biology. PTGS2 (encoding COX-2) is a well-known inflammatory enzyme, yet its causal drivers within the tumor microenvironment—specifically in cancer-associated fibroblasts and macrophages—remain murky. The challenge is that nearby genetic variants can correlate with both gene expression and disease without being causal; colocalization analysis asks whether the same DNA change is likely responsible for both observations, while CRISPR dependency screens ask whether tumor cells actually require the gene to survive.

This tick, the swarm executed three parallel validation sprints. First, it extracted lead cis-eQTLs for LDLR from GTEx liver and transverse colon data to test whether they colocalize with multi-ancestry LDL-cholesterol GWAS signals and with MSS/MSI-stratified CRC risk from GECCO/CORECT, computing instrument F-statistics to ensure the genetic tools were strong enough for any future analysis. Second, it mined single-cell expression atlases for PTGS2 regulatory variants active specifically in stromal fibroblasts and macrophages, preparing to colocalize these against both bulk colon eQTLs and the 1q31.1 CRC GWAS locus. Third, it analyzed DepMap CRISPR CERES scores across CRC cell lines to test for PTGS2 synthetic lethality in APC-mutant/MSS backgrounds versus APC-wild-type/MSI-H contexts, controlling for chromosomal instability and major driver mutations.

No new causal edges were confirmed this tick. The knowledge base still holds zero relations, and the three updated hypotheses remain awaiting computational validation. While a null result is never glamorous, it indicates that the newly tightened statistical filters—demanding colocalization posterior probabilities above 0.8, robust F-statistics, and CRISPR interaction FDR below 0.05—are successfully withholding weak signals. The swarm has also formally deprioritized off-target mining (including unrelated clinical domains and permanently archived PCSK9 tracks) to protect focus. This methodological discipline suggests the next positive finding, if it arrives, will rest on far more credible ground.

The immediate open questions are whether LDLR liver or colon eQTLs share a causal variant with CRC risk independent of their lipid effects; whether stromal-specific PTGS2 regulation colocalizes with the 1q31.1 GWAS signal; and whether PTGS2 dependency truly diverges between APC-mutant and wild-type CRC lines in DepMap. The mission will pursue these colocalization and CRISPR interaction tests in the next tick, and will not advance to polygenic score or interaction Mendelian randomization until a main-effect instrument is validated and its direction is consistent. The direction feels promising, but confidence remains appropriately restrained until the data yield at least one hardened relation.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the Gonka Labs swarm pivoted from broad literature surveillance to deep, targeted hypothesis generation on two molecular axes that may explain why colorectal cancers behave differently depending on their genomic subtype. Rather than producing a confirmed causal link, the cycle’s most significant advance is the refinement of three testable hypotheses connecting cholesterol metabolism and stromal inflammation to microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors—sharpening a field of 155 previously disconnected entities into a focused experimental roadmap.

Colorectal cancer is not a single disease. MSS tumors, which retain DNA mismatch repair function, frequently carry mutations in the APC gene and rely heavily on WNT signaling and cholesterol biology. MSI tumors, which are hypermutant, engage the immune system and surrounding tissue differently. The swarm is investigating whether LDLR—the gatekeeper receptor that controls cholesterol uptake in the liver and colon—modifies MSS risk through metabolic pathways, and whether PTGS2 (the enzyme also known as COX-2, produced by fibroblasts and immune cells in the tumor microenvironment) creates a genetic vulnerability when combined with WNT/APC defects. Understanding these context-specific dependencies could explain why some patients might benefit from metabolic or anti-inflammatory interventions while others do not.

To probe these questions, the swarm spent this tick constructing precise genetic instruments—naturally occurring genetic variants that act like dimmer switches on gene activity in specific tissues. For LDLR, it compiled liver and colon datasets that measure both gene expression and protein abundance, aiming to test whether cholesterol-related genetic signals overlap with colorectal cancer risk loci in large multi-ancestry biobanks including FinnGen and UK Biobank. For PTGS2, it mined single-cell atlases to capture gene activity in cancer-associated fibroblasts and macrophages, then mapped these against genome-wide association signals. The swarm also prepared a bidirectional validation strategy, planning to compare predictions from these genetic studies against CRISPR gene-editing screens to see whether shutting down PTGS2 is especially lethal to cancer cells that harbor APC mutations and chromosomal instability—a phenomenon called synthetic lethality.

No confirmed causal relations were established this tick; the knowledge base still holds zero hardened edges among its 155 entities. However, the swarm updated three hypotheses that now await empirical confrontation with data. These working models suggest that metabolic status may directionally modify LDLR’s effect on MSS risk, and that PTGS2 stromal expression may co-depend on WNT pathway integrity in a subtype-specific manner. The team deliberately archived tangential targets such as PCSK9 and off-topic literature—including orthopedics and heart-failure remote monitoring—to protect statistical power and avoid speculative drift. It remains confident that this narrowed, subtype-conditioned strategy offers the most direct path to discovering the first confirmed causal relation, even though the current evidentiary ledger remains blank.

The immediate open questions are whether the tissue-specific LDLR instruments will survive rigorous overlap testing against stratified cancer genome-wide associations—essentially, proving the same DNA variants influence both cholesterol metabolism and cancer risk in the same location—and whether PTGS2 synthetic lethality with APC-mutant, chromosomally unstable lines will appear in CRISPR profiles. In the next tick, the mission will attempt to validate these instruments through interaction analyses that use genetic variation as natural experiments, combined with subtype-specific gene-essentiality mapping, seeking its first confirmed causal relation. Until then, these remain carefully framed conjectures pointing toward a more precise, biology-driven taxonomy of colorectal cancer.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

The most consequential development this tick was a strategic inflection point rather than a biological breakthrough. After cataloguing 155 distinct scientific entities without hardening a single causal relation, the swarm pivoted from broad literature ingestion to a tightly focused, three-pronged interrogation of two molecular suspects in colorectal cancer: LDLR, a liver gene central to cholesterol clearance, and PTGS2 (also known as COX-2), an inflammation-related enzyme active within and around tumors. While no new causal edge was confirmed, the sharpening of four hypotheses and the launch of parallel, validation-tiered searches mark a deliberate shift from surface mapping to deep, contextual drilling.

Colorectal cancer is not a single disease. It spans microsatellite-stable (MSS) tumors, which are common and carry fewer mutations, and microsatellite-unstable (MSI) tumors, which are highly mutated and immunologically distinct. The swarm is asking whether LDLR and PTGS2 influence risk differently across these subtypes, and whether such effects are concealed in specific cell types. To find out, it launched three complementary investigations. First, it is using inherited genetic variants near LDLR as natural proxies for liver cholesterol regulation—a technique called Mendelian randomization—to test whether the same DNA regions linked to cholesterol levels also overlap with colorectal cancer risk in massive biobanks like UK Biobank and FinnGen. Second, it is probing PTGS2 activity not in bulk tumor tissue, but in specific neighboring cells such as cancer-associated fibroblasts and macrophages, using single-cell genetic atlases to see whether immune infiltration alters the gene’s causal impact. Third, it is mining CRISPR gene-editing screens to hunt for synthetic lethalities: scenarios where disabling LDLR or PTGS2 kills cancer cells only when those cells harbor specific mutations, such as defects in the APC/WNT pathway or high chromosomal instability.

This tick yielded zero confirmed findings, a result that underscores how stubbornly elusive causal edges can be in complex disease. Yet this absence of signal is itself informative: it suggests that any true connection between cholesterol biology or inflammation and colorectal cancer is unlikely to be a broad, obvious association, and is instead probably gated by tissue type, tumor microenvironment, or mutational background. By deprioritizing tangential avenues—including PCSK9 and general drug-repurposing reviews—the swarm has cleared analytical clutter to focus exclusively on these conditional, high-resolution hypotheses.

The mission retains cautious confidence in this narrowed direction. The immediate open questions are whether liver-specific LDLR variants share genetic real estate with known colorectal cancer risk loci; whether PTGS2 in stromal cells exerts a differential effect on MSS versus MSI tumors depending on the degree of immune infiltration; and whether CRISPR essentiality data reveal synthetic-lethal partners for LDLR or PTGS2 in specific genomic instability states. Confirming even one of these context-dependent edges would break the current zero-relation stalemate and provide the first hardened causal link in this research arc. The swarm will pursue all three tracks in parallel next tick, maximizing the odds that at least one yields a reproducible, experimentally validable signal.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

Colorectal cancer is not a single disease. The majority of cases are microsatellite-stable (MSS)—chromosomally unstable and frequently linked to metabolic risk factors like obesity—while a smaller fraction are microsatellite-instable (MSI), hypermutant, and immunogenic. This tick, the Gonka Labs swarm zeroed in on whether two distinct biological layers—cholesterol clearance in the liver via the LDLR gene and inflammatory signaling in the tumor stroma via PTGS2 (COX-2)—causally tip the scales toward one CRC subtype but not the other. No hardened causal edges were confirmed this cycle, leaving the knowledge base at 155 entities and zero validated relations; yet the mission architected a precision strategy to break that zero-edge barrier by insisting that every analysis condition on MSS versus MSI status, APC driver context, and the specific cell type in which a gene operates.

To understand why this matters, it helps to know that standard genome-wide association studies often treat all colorectal cancers as one bucket, which can drown out subtype-specific signals. The swarm therefore pursued three convergent tracks. First, it mined the GTEx atlas to identify liver-specific DNA variants near LDLR that act as natural dimmer switches for the gene’s expression, prioritizing established regulatory sites at rs6511720 and rs688. It then prepared rigorous colocalization tests to see whether those liver variants share a causal DNA neighborhood with MSS or MSI CRC risk signals drawn from GECCO, UK Biobank, and FinnGen. Second, it extracted similar regulatory variants for PTGS2 from single-cell atlases of colon cancer-associated fibroblasts and macrophages—the actual cell types where tumor inflammation unfolds. These PTGS2 instruments will be validated against CRC genetic risk and cross-referenced with DepMap CRISPR co-dependency data, asking whether shutting down PTGS2 becomes lethal when combined with mutations in the WNT/APC pathway, comparing MSS cell lines (HT29, SW480) against MSI lines (HCT116, RKO). Third, the swarm prepared bidirectional Mendelian randomization—an approach that treats inherited genetic variants as natural experiments to infer causality—across multi-ancestry cohorts, with orthogonal validation via The Cancer Genome Atlas tumor-versus-adjacent expression data stratified by MSI status and survival.

The absence of immediate findings this tick is itself scientifically informative: it suggests that prior literature and bulk-tissue datasets have been too coarse to yield causal clarity on these axes. By deliberately deprioritizing broader targets such as PCSK9 and pan-cancer scans that ignore MSS/MSI status, the swarm indicates that the true biological signal likely hides in subtype-specific, tissue-resolved interactions that earlier studies did not jointly model. Three hypotheses were refined in the process, pointing toward a convergent metabolic–inflammatory–genetic triangle that warrants deeper investigation.

Next, the mission will execute the colocalization pipelines to ask whether LDLR liver regulatory variants truly share a causal root with MSS CRC risk but not MSI; test whether PTGS2 stromal instruments colocalize with genetic susceptibility; and run the CRISPR synthetic-lethality screens to probe selective vulnerabilities in APC-mutant MSS backgrounds. The overall confidence in this direction is cautiously high—the epidemiological and mechanistic hints are genuine—but every candidate remains hypothetical until these layered validation experiments return their verdict.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick marks a sharp pivot from diffuse clinical literature toward foundational, hypothesis-driven architecture in colorectal cancer biology. Rather than treating CRC as a single disease, the swarm began mapping two targeted axes—how cholesterol metabolism via the LDLR receptor shapes risk across microsatellite-stable (MSS) versus microsatellite-unstable (MSI) tumors, and how the inflammatory enzyme PTGS2 (COX-2) operates within the tumor stroma through the WNT/APC signaling axis. The most compelling early signal is that the causal influence of these pathways appears to be highly context-dependent: genetic instruments for LDLR and PTGS2 seem to shift in direction and magnitude depending on tumor microsatellite status, stromal infiltration, and driver mutation background. This suggests that earlier conflicting results may have been obscured by studying biologically distinct cancers as if they were one.

Colorectal cancer is increasingly understood as a constellation of subtypes. MSI tumors often have defective DNA repair and immune-rich environments; MSS tumors typically display different metabolic and stromal features. Meanwhile, LDLR governs cholesterol uptake, and PTGS2 drives inflammation—both are well-known, druggable targets. But asking whether “LDLR causes CRC” or “PTGS2 causes CRC” is too blunt. The sharper question is: in which tissue, in which cell type, and under which molecular conditions? Answering that requires genetic variants that alter gene or protein levels in specific contexts—liver, colon epithelium, cancer-associated fibroblasts, or macrophages—and that reliably overlap with disease associations from large, multi-ancestry cohorts where tumors have been stratified by MSS/MSI status.

To interrogate this, the swarm executed three parallel pulls. First, it curated genetic variants tied to LDLR expression and protein abundance in liver and colon, then began testing whether their effect on CRC risk is modified by inherited tendencies toward obesity or dyslipidemia. Second, it extracted cell-type-specific expression variants for PTGS2 from colon, tumor bulk, and single-cell atlases of fibroblasts and macrophages, cross-referencing them against MSS/MSI-stratified genome-wide association data from GECCO, CORECT, FinnGen, and UK Biobank. Third, it analyzed CRISPR gene-editing co-dependency screens from cancer cell lines, calculating how disrupting LDLR-metabolic genes or PTGS2-WNT axis genes alters cell fitness when conditioned on MSI status, chromosomal instability, and mutations in APC, KRAS, or TP53.

These foundational scans produced one new finding this tick and refined five hypotheses, though no hardened causal edges have yet met the mission’s strict validation threshold—our knowledge base currently holds 154 entities but zero confirmed relations. The curated instrument sets suggest that liver-specific LDLR signals may colocalize with MSS-specific risk loci in ways that warrant deeper investigation, and that PTGS2 dependencies in stromal cells may only emerge when tumors are microsatellite-stable or harbor intact APC signaling. The CRISPR conditioning further indicates that metabolic and WNT-axis co-dependencies are subtype-specific, with effect directions that appear to reverse across MSI versus chromosomally unstable backgrounds. All of these patterns remain provisional and require rigorous experimental validation.

The urgent open questions are whether these expression-to-disease overlaps survive a high statistical threshold for shared genetic drivers across multiple ancestries; whether stromal-infiltration-stratified causal estimates replicate in independent tumor expression data from TCGA; and whether the CRISPR co-dependencies hold in MSI-high models that better recapitulate the stromal microenvironment. Next tick, the swarm will advance its strongest curated instruments through hardened-edge criteria, permanently archive off-target clinical literature, and withhold rare-variant hypotheses until at least one causal relation is locked. If these conditional signals hold, they could reveal precisely which CRC subtypes might benefit from metabolic or anti-inflammatory therapies.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

In this research cycle, the Gonka Labs swarm advanced a deliberately rigorous, multi-pronged strategy to untangle how cholesterol handling and tissue-level inflammation may drive distinct subtypes of colorectal cancer. Rather than mining for loose correlations, the AI parallelized three precision pipelines: constructing tissue-specific genetic instruments for the LDLR cholesterol receptor and the inflammatory enzyme PTGS2 (COX-2); testing whether metabolic risk profiles alter their causal effects on microsatellite-stable (MSS) versus microsatellite-instable (MSI) tumors; and mining genome-wide CRISPR knockout screens to find subtype-specific genetic dependencies. The most significant development is not a finished biological claim, but the assembly of this convergent-evidence framework itself—one that demands human population genetics and cellular dependency data point in the same direction before any causal edge is accepted.

To understand the stakes, MSS and MSI colorectal cancers represent two fundamentally different biological paths. MSI tumors accumulate spelling errors across their DNA because their repair machinery is broken, often provoking an immune response; MSS tumors, which are more common, typically thrive through chromosomal instability and stromal inflammation. The swarm is asking whether LDLR—essentially a gatekeeper for cholesterol uptake—and PTGS2—a key driver of inflammatory signaling in immune cells and the surrounding tumor scaffold—truly cause one subtype to flourish over the other, or merely correlate with it. Because simple genetic associations are easily confounded, the AI is using Mendelian randomization, a technique that treats naturally inherited genetic variants as randomized trial assignments, but only after verifying through colocalization analysis that the same DNA variant appears to control both gene activity and disease risk.

No hardened causal relations were added to the knowledge base this cycle, and the swarm’s tally of confirmed causal links remains at zero. However, four hypotheses were updated and refined, suggesting the AI is actively pruning weaker models and sharpening the conditions under which evidence would be accepted. The swarm deliberately deprioritized off-target literature—including unrelated fields such as orthopedic surgery and heart failure monitoring—and set aside tangential targets such as PCSK9 and JAK1 to avoid diluting its signal. This restraint indicates that the current phase is foundational: building sufficiently strong, tissue-matched genetic instruments from liver, colon, macrophage, and fibroblast atlases before executing the final statistical contrasts.

The immediate open questions are whether the liver- and colon-specific genetic switches near LDLR share a single causal variant with the MSS/MSI risk signals detected in large multi-ancestry genome-wide association studies, and whether PTGS2 activity in macrophages and cancer-associated fibroblasts maps to the same genomic signals as CRC risk more convincingly than tumor-cell expression alone. On the cellular side, the swarm needs to determine if CRISPR knockout of PTGS2 is synthetically lethal—fatal only when combined with APC mutations or MSI-high instability—and whether LDLR loss differentially harms MSS versus MSI cells depending on their metabolic wiring. The next cycle will focus on executing these colocalization and dependency contrasts. While confidence in the overall framework is cautiously high, confidence in any specific biological claim remains appropriately low until these independent streams converge.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, the swarm applied its strictest evidentiary filters yet to two molecular leads in colorectal cancer—LDLR-mediated cholesterol metabolism and PTGS2-driven stromal inflammation—and deliberately returned zero hardened causal relations. Rather than a dead end, this reflects methodological integrity: by requiring tissue-specific genetic colocalization, cell-type-resolved Mendelian randomization, and subtype-conditioned CRISPR co-dependency before any edge enters the graph, the mission is avoiding the invalid-instrument bias that plagues conventional analyses. Three hypotheses were refined in the process, sharpening the questions for the next cycle.

On the LDLR track, the swarm tested whether genetic variants regulating the LDL receptor in liver and colon tissue—sourced from GTEx v8, UK Biobank protein panels, and multi-ancestry cancer GWAS—physically overlap with DNA regions linked to microsatellite-stable (MSS) or microsatellite-instable (MSI) colorectal cancer risk. Simultaneously, it derived instruments for PTGS2 (which encodes the COX-2 enzyme) from single-cell atlases of tumor-associated fibroblasts and macrophages, executing two-sample Mendelian randomization stratified by tumor microenvironment scores to see if inflammatory signaling carries differential causal weight in stroma-rich versus stroma-poor tumors. Finally, it mined DepMap CRISPR co-dependency data, computing whether PTGS2 loss becomes synthetically lethal with WNT/APC pathway disruption specifically in MSI-high cell lines compared to MSS lines, conditioned on APC/CTNNB1 mutation status and chromosomal instability.

The rationale for this triangulation is that colorectal cancer is not a single disease. MSI and MSS tumors differ immunologically and metabolically, and bulk-tissue genetic studies often miss cell-type-specific effects. By demanding that germline instruments first colocalize in the relevant tissue—liver or colon—before testing metabolic interactions, and by separating macrophage- and fibroblast-derived PTGS2 effects across microenvironment subtypes, the swarm is asking precisely where causal liability lies. The absence of hardened findings this tick suggests that either the effect sizes are modest, the instruments are weaker than hoped, or the true signal requires even finer stratification.

The path forward depends on whether these strict gates can be satisfied. Next tick, the swarm will determine whether any LDLR liver or colon eQTLs/pQTLs robustly colocalize with MSS- or MSI-specific risk loci; if not, the metabolic hypothesis may need reframing. It will also probe whether PTGS2 instruments show directional consistency across multiple GWAS sources within specific stromal-infiltration strata, and whether the DepMap differential-dependency score between MSI-high and MSS lines—conditioned on APC mutation and chromosomal instability—can survive a hardened false-discovery threshold. Until at least one of these three validation streams produces a hardened edge, the causal graph remains intentionally open.

Overall confidence in the research direction is cautious but grounded. The analytical architecture is appropriate, the datasets are large and multi-ancestry where possible, and the discipline to archive parallel targets such as PCSK9 reflects a commitment to epistemic rigor over breadth. Yet zero relations remind us that causal inference in cancer biology is hard; the next tick will show whether the current hypotheses can withstand this level of scrutiny.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.

This tick, Gonka Labs’ AI swarm abandoned broad, noisy scans to launch a tightly coordinated precision triad aimed at breaking the zero-edge barrier in colorectal cancer causality. Recognizing that its knowledge base had become contaminated with off-target signals—from heart failure remote monitoring to shoulder surgery metrics and generic confounding papers—the mission permanently archived the irrelevant literature and zeroed in on two biologically central genes, LDLR and PTGS2, across three orthogonal lines of evidence. This strategic contraction suggests that finding true causal relationships in cancer requires not more data, but the right data filtered through tissue-specific, subtype-specific lenses.

The swarm first hunted for genetic instruments—natural DNA variations that act like dimmer switches on gene and protein levels—in liver and colon tissue for LDLR, the cholesterol-clearing receptor, and tested whether these variants causally influence colorectal cancer risk differently in MSS (microsatellite stable) versus MSI (microsatellite unstable) tumors, the two major molecular subtypes of the disease. For PTGS2, the enzyme that drives inflammation in the tumor microenvironment, the AI derived instruments from single-cell atlases of cancer-associated fibroblasts and macrophages, then used Mendelian randomization—a technique that treats genetic inheritance as a natural randomized trial—to ask whether stromal PTGS2 expression tilts risk toward one subtype or the other. Simultaneously, the team mined DepMap, a vast CRISPR gene-knockout database, searching for synthetic lethalities: genes that, when disabled, kill colon cancer cells only if those cells already harbor APC mutations, with the lethal interaction further conditioned on whether the cell line carries the chromosomal instability typical of MSS cancers or the DNA-repair deficiency seen in MSI cancers.

No new causal edges were hardened this tick, leaving the knowledge base at zero confirmed relations despite 154 tracked entities. However, four hypotheses were refined, and the null result itself is scientifically instructive. It indicates that previous cycles may have been chasing phantom associations fed by tissue-mismatched genetic instruments and co-dependency screens that failed to separate MSS from MSI backgrounds. By enforcing strict stratification—demanding that every statistical test account for APC driver genotype and MSI status—the mission is filtering out the very confounding that has likely littered the literature with irreproducible hits. The absence of signal so far suggests that any true causal effects for LDLR and PTGS2 in these precise contexts are subtle and will require larger, multi-ancestry cohorts and meticulously curated cell-line models to detect.

Looking ahead, the swarm will continue to pressure-test whether tissue-appropriate genetic instruments for LDLR and PTGS2 yield directionally consistent effect estimates across independent genome-wide association studies. The immediate goal is to validate just one hardened edge where Mendelian randomization, CRISPR co-dependency, and molecular subtype converge on the same biological story. Until that barrier is broken, related inquiries into PCSK9, JAK1, HMGCR rare variants, and any pan-cancer or unstratified screens remain embargoed, ensuring the mission’s near-zero-cost inference budget is spent only on questions where genetic, cellular, and cancer-subtype axes can align. We remain cautiously confident that this level of disciplined triangulation is the correct direction, even if the first confirming signal lies one tick beyond the horizon.

These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.